RE: Scib trial details4 Nov 2019 12:51
While cost is a primary consideration for NICE, I'm sure they weigh this against effectiveness, so if SCIB1 significantly boosts the response that ought to be good news all round.
You make a good point though,, and presumably the US would be a more certain market if medical insurance is expected to fund whatever available treatment works.